BF2.649 (Pitolisant)
Narcolepsy (Type 1 & 2)
Phase 3Patient enrollment completed, NDA preparation underway
Key Facts
Indication
Narcolepsy (Type 1 & 2)
Phase
Phase 3
Status
Patient enrollment completed, NDA preparation underway
Company
About Aculys Pharma
A Japanese neuroscience biotech addressing drug lag by licensing and commercializing overseas-approved treatments for epilepsy and sleep disorders.
View full company profileAbout Aculys Pharma
A Japanese neuroscience biotech addressing drug lag by licensing and commercializing overseas-approved treatments for epilepsy and sleep disorders.
View full company profileTherapeutic Areas
Other Narcolepsy (Type 1 & 2) Drugs
| Drug | Company | Phase |
|---|---|---|
| Mazindol ER (NLS-4 / Quilience®) | NLS Pharmaceutics | Phase 3 |